Health Catalyst (HCAT) Stock Forecast & Price Target

Compare

451 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HCAT Analyst Ratings

Moderate Buy

3 Buy

7 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Health

Catalyst

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HCAT Stock 12 Month Forecast

Average Price Target

$4.31

▲(53.93% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Health Catalyst in the last 3 months. The average price target is $4.31 with a high forecast of $6.00 and a low forecast of $3.50. The average price target represents a 53.93% change from the last price of $2.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","4":"$4","6":"$6","8":"$8","10":"$10"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4,6,8,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,3.6,3.8,4,4.2,4.4,4.6,4.8,5,5.2,5.4,5.6,5.800000000000001,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,3.4699999999999998,3.54,3.61,3.6799999999999997,3.75,3.82,3.8899999999999997,3.96,4.029999999999999,4.1,4.17,4.239999999999999,{"y":4.31,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,3.4076923076923076,3.4153846153846152,3.423076923076923,3.4307692307692306,3.4384615384615382,3.446153846153846,3.453846153846154,3.4615384615384617,3.4692307692307693,3.476923076923077,3.4846153846153847,3.4923076923076923,{"y":3.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.19,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.02,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.33,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$6.00

Average Price Target$4.31

Lowest Price Target$3.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Sarah James

Cantor Fitzgerald

Hold

42.86%

Upside

Reiterated

09/08/25

Health Catalyst (HCAT) Receives a Hold from Cantor Fitzgerald

David Larsen

BTIG

―

Hold

―

Reiterated

09/05/25

Cautious Hold Rating on Health Catalyst Amid Regulatory and Transition Challenges

Isla Carelynx

TR | OpenAI - 4o

$3.5

Hold

25.00%

Upside

Reiterated

09/03/25

AI Generated ArticleAI Generated Article

Ryan Daniels

William Blair

―

Buy

―

Reiterated

09/02/25

Health Catalyst: Strong Buy Rating Amidst Long-Term Growth Prospects and Industry LeadershipWe recently attended the three-day 2025 (HAS 25) in Utah—the annual client and user group conference hosted by Health Catalyst. The event was well attended, in our view, with attendees representing a diverse mix of data and analytics professionals, clinicians, and health system executives.

Richard Close

Canaccord Genuity

$9→$5

Buy

78.57%

Upside

Reiterated

08/29/25

Health Catalyst price target lowered to $5 from $9 at CanaccordHealth Catalyst price target lowered to $5 from $9 at Canaccord

David Grossman

Stifel Nicolaus

$4.5

Hold

60.71%

Upside

Reiterated

08/29/25

Elizabeth Anderson CFA

Evercore ISI

$3→$4

Hold

42.86%

Upside

Reiterated

08/28/25

Evercore ISI Sticks to Their Hold Rating for Health Catalyst (HCAT)

Jessica Tassan

Piper Sandler

$8→$4

Hold

42.86%

Upside

Downgraded

08/27/25

Health Catalyst downgraded to Neutral from Overweight at Piper SandlerHealth Catalyst downgraded to Neutral from Overweight at Piper Sandler

Stan Berenshteyn

Wells Fargo

$10→$6

Buy

114.29%

Upside

Reiterated

08/11/25

Health Catalyst's Strategic Restructuring and Cost Management Justify Buy Rating Despite Revenue Guidance Reduction

Daniel Grosslight

Citi

$6.5→$3.5

Hold

25.00%

Upside

Downgraded

08/08/25

Health Catalyst downgraded to Neutral from Buy at CitiHealth Catalyst downgraded to Neutral from Buy at Citi

Anne Samuel

J.P. Morgan

Buy

221.43%

Upside

Reiterated

05/20/25

Health Catalyst (HCAT) Receives a Buy from J.P. Morgan

Scott Schoenhaus

KeyBanc

$7→$5

Buy

78.57%

Upside

Reiterated

04/16/25

KeyBanc Remains a Buy on Health Catalyst (HCAT)

Jeffrey Garro

Stephens

$7→$5

Hold

78.57%

Upside

Reiterated

03/06/25

Health Catalyst price target lowered to $5 from $7 at StephensHealth Catalyst price target lowered to $5 from $7 at Stephens

Sean Dodge

RBC Capital

$7→$6

Hold

114.29%

Upside

Reiterated

02/26/25

Health Catalyst (HCAT) Receives a Hold from RBC Capital

Stephanie Davis

Barclays

$14

Buy

400.00%

Upside

Reiterated

11/07/24

Barclays Sticks to Their Buy Rating for Health Catalyst (HCAT)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Sarah James

Cantor Fitzgerald

Hold

42.86%

Upside

Reiterated

09/08/25

Health Catalyst (HCAT) Receives a Hold from Cantor Fitzgerald

David Larsen

BTIG

―

Hold

―

Reiterated

09/05/25

Cautious Hold Rating on Health Catalyst Amid Regulatory and Transition Challenges

Isla Carelynx

TR | OpenAI - 4o

$3.5

Hold

25.00%

Upside

Reiterated

09/03/25

AI Generated ArticleAI Generated Article

Ryan Daniels

William Blair

―

Buy

―

Reiterated

09/02/25

Richard Close

Canaccord Genuity

$9→$5

Buy

78.57%

Upside

Reiterated

08/29/25

Health Catalyst price target lowered to $5 from $9 at CanaccordHealth Catalyst price target lowered to $5 from $9 at Canaccord

David Grossman

Stifel Nicolaus

$4.5

Hold

60.71%

Upside

Reiterated

08/29/25

Elizabeth Anderson CFA

Evercore ISI

$3→$4

Hold

42.86%

Upside

Reiterated

08/28/25

Evercore ISI Sticks to Their Hold Rating for Health Catalyst (HCAT)

Jessica Tassan

Piper Sandler

$8→$4

Hold

42.86%

Upside

Downgraded

08/27/25

Health Catalyst downgraded to Neutral from Overweight at Piper SandlerHealth Catalyst downgraded to Neutral from Overweight at Piper Sandler

Stan Berenshteyn

Wells Fargo

$10→$6

Buy

114.29%

Upside

Reiterated

08/11/25

Health Catalyst's Strategic Restructuring and Cost Management Justify Buy Rating Despite Revenue Guidance Reduction

Daniel Grosslight

Citi

$6.5→$3.5

Hold

25.00%

Upside

Downgraded

08/08/25

Health Catalyst downgraded to Neutral from Buy at CitiHealth Catalyst downgraded to Neutral from Buy at Citi

Anne Samuel

J.P. Morgan

Buy

221.43%

Upside

Reiterated

05/20/25

Health Catalyst (HCAT) Receives a Buy from J.P. Morgan

Scott Schoenhaus

KeyBanc

$7→$5

Buy

78.57%

Upside

Reiterated

04/16/25

KeyBanc Remains a Buy on Health Catalyst (HCAT)

Jeffrey Garro

Stephens

$7→$5

Hold

78.57%

Upside

Reiterated

03/06/25

Health Catalyst price target lowered to $5 from $7 at StephensHealth Catalyst price target lowered to $5 from $7 at Stephens

Sean Dodge

RBC Capital

$7→$6

Hold

114.29%

Upside

Reiterated

02/26/25

Health Catalyst (HCAT) Receives a Hold from RBC Capital

Stephanie Davis

Barclays

$14

Buy

400.00%

Upside

Reiterated

11/07/24

Barclays Sticks to Their Buy Rating for Health Catalyst (HCAT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Health Catalyst

1 Month

xxx

Success Rate

12/24 ratings generated profit

Average Return

+1.35%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +1.35% per trade.

3 Months

xxx

Success Rate

11/24 ratings generated profit

Average Return

+2.69%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 45.83% of your transactions generating a profit, with an average return of +2.69% per trade.

1 Year

Richard CloseCanaccord Genuity

Success Rate

5/24 ratings generated profit

Average Return

-24.43%

reiterated a buy rating last month

Copying Richard Close's trades and holding each position for 1 Year would result in 20.83% of your transactions generating a profit, with an average return of -24.43% per trade.

2 Years

xxx

Success Rate

2/24 ratings generated profit

Average Return

-52.38%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 8.33% of your transactions generating a profit, with an average return of -52.38% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HCAT Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HCAT has received 6 Buy Ratings, 24 Hold Ratings, and 0 Sell Ratings. HCAT average Analyst price target in the past 3 months is 4.31.

Each month's total comprises the sum of three months' worth of ratings.

HCAT Financial Forecast

HCAT Earnings Forecast

Next quarter’s earnings estimate for HCAT is $0.06 with a range of $0.03 to $0.09. The previous quarter’s EPS was $0.04. HCAT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year HCAT has Outperformed its overall industry.

HCAT Sales Forecast

Next quarter’s sales forecast for HCAT is $76.80M with a range of $74.91M to $85.00M. The previous quarter’s sales results were $80.72M. HCAT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year HCAT has Outperformed its overall industry.

HCAT Stock Forecast FAQ

What is HCAT’s average 12-month price target, according to analysts?

Based on analyst ratings, Health Catalyst’s 12-month average price target is 4.31.

What is HCAT’s upside potential, based on the analysts’ average price target?

Health Catalyst has 53.93% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HCAT a Buy, Sell or Hold?

Health Catalyst has a consensus rating of Moderate Buy which is based on 3 buy ratings, 7 hold ratings and 0 sell ratings.

What is Health Catalyst’s price target?

The average price target for Health Catalyst is 4.31. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $6.00 ,the lowest forecast is $3.50. The average price target represents 53.93% Increase from the current price of $2.8.

What do analysts say about Health Catalyst?

Health Catalyst’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of HCAT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Health Catalyst (HCAT) Stock Forecast & Price Target

HCAT Analyst Ratings

HCAT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Health Catalyst

HCAT Analyst Recommendation Trends

HCAT Financial Forecast

HCAT Earnings Forecast

HCAT Sales Forecast

HCAT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts